GM1 Gangliosidosis Gene Therapy Study
Contact
Description
Eligibility and criteria
IRB Number:
20-017647
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
- Receiving the investigational study drug (PBGM01) one time via an injection into the space just below the brain (intracisternal injection).
- Taking oral steroids for approximately two months.
- Undergoing a series of research blood and urine tests, physical and neurological exams, cognitive and behavioral assessments, lumbar punctures (LP), ultrasounds, hearing and vision tests, nerve conduction studies, spinal x-rays, and MRIs.
- Having some of these study procedures performed under general anesthesia.
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.